Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

NCT03566485 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped Low accrual/Loss of funding

Conditions

Stage III Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Estrogen Receptor-positive
HER2/Neu Negative

Interventions

DRUG: Atezolizumab
DRUG: Cobimetinib
DRUG: Idasanutlin

Sponsor

Vanderbilt-Ingram Cancer Center

Collaborators

[object Object]
[object Object]